Drug sensitivity profiling identifies potential therapies for myeloid neoplasm with eosinophilia driven by a novel G3BP1-PDGFRB fusion gene

Leuk Lymphoma. 2024 Apr;65(4):521-525. doi: 10.1080/10428194.2023.2299298. Epub 2023 Dec 29.

Authors

Jianli Wang¹, Lei Xu², Yuqing Li^{2

3}, Jun Wang², Yangliu Shao^{2

3}, Weifeng Lai⁴, Jun Yong⁴, Ling Zhao⁵, Xuemin Wei⁵, Chunji Gao⁵, Daihong Liu⁵, Xiaoning Gao², Yongqing Zhang^{1

5}

Affiliations

¹ Department of Internal Medicine, Hebei North University, Zhangjiakou, China.
² Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
³ Graduate School of Chinese PLA General Hospital, Beijing, China.
⁴ Suzhou Geekgene Technology Co. Ltd., Beijing, China.
⁵ Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

PMID: 38157478
DOI: 10.1080/10428194.2023.2299298

No abstract available

MeSH terms

DNA Helicases
Eosinophilia* / diagnosis
Eosinophilia* / drug therapy
Eosinophilia* / genetics
Humans
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / drug therapy
Myeloproliferative Disorders* / genetics
Neoplasms*
Oncogene Proteins, Fusion / genetics
Poly-ADP-Ribose Binding Proteins
RNA Helicases / therapeutic use
RNA Recognition Motif Proteins
Receptor, Platelet-Derived Growth Factor beta / genetics

Substances

Receptor, Platelet-Derived Growth Factor beta
DNA Helicases
Poly-ADP-Ribose Binding Proteins
RNA Helicases
RNA Recognition Motif Proteins
Oncogene Proteins, Fusion
G3BP1 protein, human
PDGFRB protein, human